STAT3 encounters other post-translational modifications such as phosphorylation on Serine residue 727 (S-P), which also appears to be involved in the control of metabolic processes. Indeed, S-P STAT3 localizes into the mitochondria, where it preserves oxidative phosphorylation and opposes the opening of the mitochondrial permeability transition pore, thus inhibiting apoptosis 12, 13 . This function was shown to be required for tumor transformation mediated by oncogenic RAS, paradoxically favoring both aerobic glycolysis and ETC activity 14 . STAT3 appears therefore to function as a hub to integrate different oncogenic signals, via both mitochondrial and nuclear activities 15 ( Fig. 1 ). An outstanding question remains how STAT3 would exert its activity within the mitochondrion, since its very low abundance in this organelle challenges the proposed mechanism based on the interaction with specific electron transport complexes of the mitochondrial inner membrane 16 .
STAT3 chemical or genetic inhibition accelerates the autophagic flux due to an inhibitory interaction of the STAT3 SH2 domain with the cytoplasmic PKR kinase 17 .
Interfering with either the STAT3 cytoplasmic localization, through constitutive or acute Y-P activation, or with its SH2 domain, using specific drugs such as STATTIC or S3I, may in principle increase the pool of free PKR and basal autophagy (Fig. 1) . This relatively straightforward mechanism, however, fails to explain why also inhibitors that indirectly prevent STAT3 phosphorylation, such as the Jak kinase inhibitor WP1066, were also able to We and others have shown that the chronic transcriptional activity of STAT3 is able to act as a first hit in the process of malignant transformation 20 . Moreover, the level of circulating IL-6, one of the best characterized STAT3-activating factors, increases with age, thus supporting a possible age-dependent chronic STAT3 tyrosine-activation 21 . Since aging is the single factor with the highest impact on cancer initiation, interfering with STAT3 transcriptional activity may be useful as a prophylactic therapy to reduce the rate of cellular transformation. Systemic prophylactic STAT3 blockade by means of specific inhibitors would presumably be too toxic, due to continued inhibition of its physiological functions, but effective results might be achieved by chronic anti-inflammatory treatments.
Once the tumor is already established, however, inhibiting STAT3 transcriptional activity will eventually increase the pool of monomeric protein in the cancer cells. We have
shown that chemically interfering with the constitutively activated form of STAT3 leads to a 'counter-switch' to oxidative phosphorylation 10 . On one side, this effect will initially slow down proliferation and adaptation to a hypoxic environment. On the other side, the increased abundance of monomeric STAT3 may increase its availability for mitochondrial localization, which might eventually lead to enhanced ATP production and glycolysis rate, as previously Adenine nucleotide translocator (ANT); Voltage-dependent anion channel (VDAC).
